GLP-1 Drugs Repositioned as Lifestyle Products Amid Slowing Insurance Coverage

GLP-1 drugs, once marketed as treatments for obesity, are increasingly being repositioned by pharmaceutical companies like Novo Nordisk as lifestyle products that can help patients feel better and look younger. This shift in marketing strategy is a response to the slow expansion of insurance coverage for these high-priced medications.

According to STAT, early efforts to market GLP-1s focused on convincing payers and society that obesity was a disease requiring treatment. However, with insurance coverage stalling due to the drugs' high price and usage, companies like Novo Nordisk began selling their products directly to patients.

Meanwhile, Merck and Daiichi Sankyo have withdrawn their U.S. application for accelerated approval of an experimental lung cancer therapy. This decision follows discussions with the FDA, which determined that data from a mid-stage clinical study did not meet requirements for early approval. The therapy was under review to treat adults with aggressive, extensive-stage small cell lung cancer.